Why I’d pick the GSK and AstraZeneca share prices to beat my State Pension

I’m looking to re-invest a company pension, and here’s why AstraZeneca plc (LON: AZN) and GlaxoSmithKline plc (LON: GSK) shares are on my list.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

After a lengthy process, I have managed to free up an old company pension and have it transferred to a SIPP. It was an old-style defined benefits scheme, and a good few hoops needed to be jumped through — but my pension provider made me what I considered a very good enhanced offer, and also paid for the independent advice I needed legally to make the move.

My big question now is what shares to invest in, and it’s going to be almost entirely FTSE 100 companies — I reckon they’re by far the best choices for beating the State Pension of approximately £8,500 per year.

“Aren’t people worried about Brexit?” asked a friend the other day when we were chatting about share investment, and yes they clearly are. But the FTSE 100 is full of multinational companies whose businesses will barely notice the UK’s exit from the EU, however badly it goes.

Cracking recovery

A look at the AstraZeneca (LSE: AZN) share price, which has gained 15% over the past 12 months, tells me two things. One is that investors are finally warming to the company’s turnaround under the leadership of Pascal Soriot (which was always going to take a signficant number of years), and the other is that there’s been a so-called flight to quality as people abandon what they see as Brexit risk and buy shares they see as safer.

That does reinforce my feeling that the best long-term strategy is to always buy shares in safer high-quality companies paying good dividends, regardless of the political and economic environment. And I am bemused when folk apparently think that buying quality only matters when the most apt fruit-based analogy for the shape of the economy is that of the pear.

The recovery in AstraZeneca’s earnings per share is forecast to kick in strongly over the next two years, with double-digit growth on the cards for 2020 putting the shares on a PEG ratio of 0.7 — and that’s good for a small-cap growth company, never mind a FTSE 100 giant.

A 2020 P/E of 17 is not demanding in my view, and a very well covered forecast dividend yield of 3.7% is one that I expect to be set for a long spell of progressive rises.

Better value?

If you’d prefer a bigger dividend now, the City has GlaxoSmithKline (LSE: GSK) pegged at a yield of 5.3%. Glaxo shares are also trading on forward P/E multiples of around 12 to 13, though there isn’t the same earnings growth on the cards as we see at AstraZeneca. The shares still look cheap to me, but why?

At the end of 2018, Glaxo revealed that it plans to shed its consumer healthcare division and merge it with Pfizer, creating a business with annual sales close to £10bn and which will be split out into a new FTSE-listed company within three years.

It’s clearly a profitable business, and there will be some who think letting it go is a mistake. But ace investor Neil Woodford has been the vocal personification of those who think a break-up is better for years. After all, drug development is a very different business to retail healthcare, and AstraZeneca’s refocus on its core strength has done it a world of good.

I think the same will be true of GlaxoSmithKline, and it’s firmly on my list of pension candidates.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Under £14 now, Persimmon’s share price is trading at less than half its fair value by my reckoning

Persimmon’s share price fell a lot over the past year, but I think a new home-building initiative and improved macroeconomic…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Is this FTSE 100 pharma gem now a brilliant bargain?

This FTSE 100 pharmaceutical giant has been hit by fears of US tariffs and litigation over a key product, but…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Is Warren Buffett losing his touch?

Our writer's noticed that Warren Buffett’s investment vehicle has underperformed the S&P 500 during three of the past four years.…

Read more »

Investing Articles

Non-energy minerals are the top performers in 2025. These small-cap FTSE shares are leading the charge

Mark Hartley examines which sectors are doing well in 2025 and the FTSE shares that investors should consider to benefit…

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

Buying 10,000 Vodafone shares generates a passive income of…

Vodafone shares have had a rough ride, with dividends slashed in half. But with its turnaround making steady progress, is…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Buying 1,000 Aviva shares generates an income of…

Aviva shares could be primed to thrive in the long run if its takeover of Direct Line is a success,…

Read more »

Investing Articles

At today’s price, buying 1,000 British American Tobacco shares generates a second income of…

Tobacco companies may not be popular, but the British American Tobacco share price is on the rise, along with its…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

The cheapest UK stock in my ISA is…

This UK stock currently trades at a massive discount to the market. Edward Sheldon believes it's mispriced and that there's…

Read more »